Clinical Trials Logo

Malignant Neoplasm of Stomach clinical trials

View clinical trials related to Malignant Neoplasm of Stomach.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02528110 Completed - Clinical trials for Malignant Neoplasm of Stomach

Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy plus HIPEC is superior to only radical gastrectomy in terms of overall survival.

NCT ID: NCT02337673 Completed - Liver Diseases Clinical Trials

Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography

Start date: May 2014
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to determine whether Electrical Impedance Tomography can be used as sensitive and specific predictor in the detection of postoperative pulmonary complications (e.g. pneumonia, bronchitis, acute respiratory distress syndrome, pleural effusion, pneumothorax, pulmonary edema, atelectasis, pulmonary embolism, hypoxemia, hypercapnia, spasms and obstructions of the airway) in patients undergoing epigastric surgery.

NCT ID: NCT02158988 Completed - Clinical trials for Malignant Neoplasm of Stomach

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis

GASTRIPEC
Start date: March 1, 2014
Phase: Phase 3
Study type: Interventional

Patients with histological proven gastric cancer (including cancer of the esophagogastric junction (AEG)) and synchronous peritoneal carcinomatosis, who fulfill the inclusion and exclusion criteria, can be recruited in this study. There are two treatment groups (A and B). The chemotherapy applied intravenously is the same in both groups and is approved for the treatment of gastric cancer. Patients with negative or unknown HER-2 status will be administered Epirubicin, Oxaliplatin and Capecitabine (EOX). Patients with positive HER-2 status will be treated with Cisplatin, Capecitabine and Trastuzumab (CCT). The chemotherapy is followed by surgical cytoreduction in both groups. Patients randomized into group B will be treated with an intraperitoneal (in the abdominal cavity) chemoperfusion with Mitomycin C and Cisplatin . Patients in both groups receive 3 cycles of postoperative chemotherapy within 4-12 weeks after the surgical procedure and are followed up for 30 months. If progress of the tumor is detected the patient will no longer be treated according to the study therapy. Patients of group B may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs applied can be excluded.

NCT ID: NCT01758965 Completed - Clinical trials for Malignant Neoplasm of Stomach

Surgicel® Fibrillar for Delayed Bleeding After ESD

Start date: December 2012
Phase: N/A
Study type: Interventional

The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors

NCT ID: NCT01443065 Completed - Clinical trials for Malignant Neoplasm of Stomach

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

MEGA
Start date: January 2011
Phase: Phase 2
Study type: Interventional

This multicentre, open-label, randomized phase II trial is ongoing in 30 centres in France. Main eligibility criteria include: histologically proven adenocarcinoma of the stomach, esophagus or gastroesophageal junction; locally advanced or metastatic disease; measurable disease (RECIST 1.1); no known HER2 overexpression; no prior palliative chemotherapy.

NCT ID: NCT01187212 Completed - Clinical trials for Effects of Chemotherapy

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.